Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions

被引:26
作者
Clarke, John D. [1 ]
Cherrington, Nathan J. [1 ]
机构
[1] Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA
关键词
adverse drug reaction; drug metabolism; non-alcoholic fatty liver disease; organic anion transport polypeptide; pharmacogenetics; HEART-TRANSPLANT RECIPIENT; MEDIATED HEPATIC-UPTAKE; NECROSIS-FACTOR-ALPHA; FATTY LIVER-DISEASE; DOWN-REGULATION; HEPATOCELLULAR-CARCINOMA; SLCO1B3; GENE; CYCLOSPORINE-A; MESSENGER-RNA; BILE-ACID;
D O I
10.1517/17425255.2012.656087
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Organic anion transporting polypeptide (OATP) uptake transporters are important for the disposition of many drugs and perturbed OATP activity can contribute to adverse drug reactions (ADRs). It is well documented that both genetic and environmental factors can alter OATP expression and activity. Genetic factors include single nucleotide polymorphisms (SNPs) that change OATP activity and epigenetic regulation that modify OATP expression levels. SNPs in OATPs contribute to ADRs. Environmental factors include the pharmacological context of drug-drug interactions and the physiological context of liver diseases. Liver diseases such as nonalcoholic fatty liver disease, cholestasis and hepatocellular carcinoma change the expression of multiple OATP isoforms. The role of liver diseases in the occurrence of ADRs is unknown. Areas covered: This article covers the roles OATPs play in ADRs when considered in the context of genetic or environmental factors. The reader will gain a greater appreciation for the current evidence regarding the salience and importance of each factor in OATP-mediated ADRs. Expert opinion: A SNP in a single OATP transporter can cause changes in drug pharmacokinetics and contribute to ADRs but, because of overlap in substrate specificities, there is potential for compensatory transport by other OATP isoforms. By contrast, the expression of multiple OATP isoforms is decreased in liver diseases, reducing compensatory transport and thereby increasing the probability of ADRs. To date, most research has focused on the genetic factors in OATP-mediated ADRs while the impact of environmental factors has largely been ignored.
引用
收藏
页码:349 / 360
页数:12
相关论文
共 84 条
[1]  
Adverse Events Reporting System. U S Food and Drug Administration, 2011, ADV EV REP SYST
[2]   Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005 [J].
Altekruse, Sean F. ;
McGlynn, Katherine A. ;
Reichman, Marsha E. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1485-1491
[3]   GI Epidemiology: nonalcoholic fatty liver disease [J].
Angulo, P. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (08) :883-889
[4]   Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice [J].
Bailey, D. G. ;
Dresser, G. K. ;
Leake, B. F. ;
Kim, R. B. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (04) :495-502
[5]   Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin [J].
Brunham, L. R. ;
Lansberg, P. J. ;
Zhang, L. ;
Miao, F. ;
Carter, C. ;
Hovingh, G. K. ;
Visscher, H. ;
Jukema, J. W. ;
Stalenhoef, A. F. ;
Ross, C. J. D. ;
Carleton, B. C. ;
Kastelein, J. J. P. ;
Hayden, M. R. .
PHARMACOGENOMICS JOURNAL, 2012, 12 (03) :233-237
[6]   Tissue distribution and ontogeny of mouse organic anion transporting polypeptides (Oatps) [J].
Cheng, XG ;
Maher, J ;
Chen, C ;
Klaassen, CD .
DRUG METABOLISM AND DISPOSITION, 2005, 33 (07) :1062-1073
[7]   Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats [J].
Cherrington, NJ ;
Slitt, AL ;
Li, N ;
Klaassen, CD .
DRUG METABOLISM AND DISPOSITION, 2004, 32 (07) :734-741
[8]   Detection of the human organic anion transporters SLUM (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma [J].
Cui, YH ;
König, J ;
Nies, AT ;
Pfannschmidt, M ;
Hergt, M ;
Franke, WW ;
Alt, W ;
Moll, R ;
Keppler, D .
LABORATORY INVESTIGATION, 2003, 83 (04) :527-538
[9]   Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-Episodes [J].
Davies, Emma C. ;
Green, Christopher F. ;
Taylor, Stephen ;
Williamson, Paula R. ;
Mottram, David R. ;
Pirmohamed, Munir .
PLOS ONE, 2009, 4 (02)
[10]   Obstructive cholestasis induces TNF-α- and IL-1β-mediated periportal downregulation of Bsep and zonal regulation of Ntcp, Oatp1a4, and Oatp1b2 [J].
Donner, Markus G. ;
Schumacher, Stephanie ;
Warskulat, Ulrich ;
Heinemann, Jane ;
Haeussinger, Dieter .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2007, 293 (06) :G1134-G1146